Long-Term Mood/Antidepressant Effects of Quetiapine Extended-Release Formulation: An Open-Label, Non-Controlled Extension Study in Japanese Patients With Bipolar Depression

BMC Psychiatry - United Kingdom
doi 10.1186/s12888-019-2181-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Efficacy and Safety of Once-Daily Quetiapine Extended Release in Patients With Schizophrenia Switched From Other Antipsychotics: An Open-Label Study in Chinese Population

BMC Psychiatry
PsychiatryMental Health
2015English

Long-Term Metformin Treatment in Adolescents With Obesity and Insulin Resistance, Results of an Open Label Extension Study

Nutrition and Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

SAT0236 Long-Term Safety and Efficacy of Upadacitinib (ABT-494), an Oral Jak-1 Inhibitor in Patients With Rheumatoid Arthritis in an Open Label Extension Study

2018English

PMH29 Cost Effectiveness of Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Turkey in Patients With Major Depressive Disorder (Mdd) Who Have Failed Previous Antidepressant Therapy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

An Open-Label, Prospective Study of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Long-Term Treatment of Refractory Depression

Journal of Clinical Psychiatry
MedicinePsychiatryMental Health
2008English

Ziprasidone in Adolescents With Schizophrenia: Results From a Placebo-Controlled Efficacy and Long-Term Open-Extension Study

Journal of Child and Adolescent Psychopharmacology
Mental HealthChild HealthPharmacologyPerinatologyPsychiatryPediatrics
2013English

Long-Term Safety and Tolerability of Oral Tofacitinib in Patients With Crohn’s Disease: Results From a Phase 2, Open-Label, 48-Week Extension Study

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2019English

Long-Term Safety of Siltuximab in Patients With Idiopathic Multicentric Castleman Disease: A Prespecified, Open-Label, Extension Analysis of Two Trials

The Lancet Haematology
Hematology
2020English

Long-Term Efficacy and Safety of RPC4046, an Anti-Interleukin-13 Monoclonal Antibody, in Patients With Eosinophilic Esophagitis: Results From the Open-Label Extension of the HEROES Study

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy